ESR1 and breast carcinoma: Neoadjuvant NEWEST trial showed that in 211 early breast cancer patients, the 500 mg regimen of fulvestrant resulted in a significantly (p < 0.0003) greater reduction in ER expression compared with the 250-mg dose at week 4 (22 vs 15%) [121].